Stock events for Pulmonx Corp. (LUNG)
Pulmonx Corp. (LUNG) stock has experienced significant volatility in the past six months. The 52-week high for the stock was $8.12, and the 52-week low was $1.31. As of March 2, 2026, the share price was $1.52, a notable decrease from $8.29 on March 3, 2025. Key events include reporting fourth quarter and full-year 2025 financial results, closing a new credit facility, announcing inducement grants, reporting third-quarter 2025 financial results, announcing a management transition and preliminary third-quarter 2025 revenue, and implementing a cost restructuring initiative. The company also experienced significant turnover in its U.S. sales organization.
Demand Seasonality affecting Pulmonx Corp.’s stock price
Seasonality in the demand for Pulmonx's products and services has been observed. In 2022, seasonality impacted both the U.S. and international markets. However, in 2023, the company demonstrated an ability to navigate through this seasonality in the U.S. market.
Overview of Pulmonx Corp.’s business
Pulmonx Corporation is a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, a form of COPD. Their main product is the Zephyr® Endobronchial Valve, a one-way valve that blocks off diseased portions of the lung. They also offer the Chartis® Pulmonary Assessment System for patient selection and the StratX® Lung Analysis Platform, a cloud-based CT analysis service, along with LungTraX Platform for improved workup efficiency and patient identification.
LUNG’s Geographic footprint
Pulmonx Corporation has a global presence, serving patients in the United States, Europe, the Middle East, Africa, and the Asia Pacific region. The company has a strong market presence in North America, Europe, and Asia, and its Zephyr Valve is commercially available in more than 25 countries.
LUNG Corporate Image Assessment
Pulmonx has a strong brand reputation for its Zephyr® Endobronchial Valve, which has received FDA pre-market approval and is included in global treatment guidelines. The company emphasizes its commitment to improving the lives of patients with chronic respiratory diseases. However, the significant decline in stock price and challenges in U.S. market adoption could indirectly influence public and investor perception.
Ownership
The ownership structure of Pulmonx Corp. (LUNG) is primarily a mix of institutional, insider, and public investors. Institutional investors hold approximately 66.12% to 80.9% of the company's stock, while insiders own about 11.68% to 12.81%. Public companies and individual investors hold roughly 14.7% to 21.07% of the shares. Major institutional owners include Primecap Management Co/ca/, Morgan Stanley, and BlackRock, Inc. Among individual investors, Theofanis Kolokotrones is noted as owning the most shares.
